Veterans Affairs Medical Center -Washington DC

Summary

Veterans Affairs Medical Center -Washington DC is a medical facility located in Miami, Florida. This center is recognized for care of Lung Cancer, Head and Neck Cancers, Lymphoma, Squamous Cell Carcinoma, HIV Infection and other specialties. Veterans Affairs Medical Center -Washington DC is involved with conducting 212 clinical trials across 355 conditions. There are 12 research doctors associated with this hospital, such as George Kurdgelashvili, MD, Jared M. Gollie, PhD, Anita Aggarwal, and Debra Benator, MD.

Top PIs

Clinical Trials running at Veterans Affairs Medical Center -Washington DC

Prostate Cancer

Fanconi Anemia

HIV/AIDS

Liver Cancer

Multiple Sclerosis

Fatigue

Silent Stroke

Colorectal polyposis syndrome

Hereditary Sensory Neuropathy

Breast and ovarian cancer syndrome

Pembrolizumab

for Prostate Cancer

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.

Recruiting

2 awards

Phase 2

3 criteria

Carboplatin vs Olaparib

for Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Recruiting

1 award

Phase 2